Genmab has named Matt Kiely as General Manager for the United Kingdom, marking a key step in its European commercial expansion. The appointment supports the company’s mission to deliver antibody-based medicines to more patients with cancer.
Founded in Copenhagen in 1999, Genmab specialises in antibody science and operates internationally. The UK appointment reflects its strategy to build a stronger presence across Europe and prepare for future product launches.
Matt joins Genmab with over 20 years of global pharmaceutical leadership, including senior roles at GSK, Takeda and Stemline Therapeutics. His expertise spans oncology, market access and organisational development.
Brad Bailey, Executive Vice President and Chief Commercial Officer, said: “Welcoming Matt to our team is a significant step in our mission to bring innovative medicines to more patients around the world. His outstanding track record in building high-performing organisations and launching successful cancer therapies makes him the ideal leader to drive our expansion in the UK, ensuring that we can deliver on our goal to bring treatments to patients in need.”
Matt will oversee UK business operations and lead efforts to establish Genmab’s commercial presence. He officially joined the company on 1 September.
He said: “Throughout my career, I have been passionate about oncology innovation and am excited to join Genmab, a company at the forefront of antibody science and with a strong commitment to putting patients first. The UK healthcare environment holds potential for Genmab to make a difference for patients.”
